This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Sonnenberg, G. E Articles by Reinhardt, R. R Search for Related Content Social Bookmarking                         What's this?

Review: Drug treatments for obesity: where are we heading and how do we get there?

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA, gsnn{at}novonordisk.com

Glenn Matfin

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA

Rickey R Reinhardt

Clinical Pharmacology and Research, Novo Nordisk Inc.,100 College Road West, Princeton, New Jersey 08540, USA

Obesity has reached epidemic proportions with an estimated 1.7 billion people worldwide classified as either overweight or obese. Obesity is associated with multiple co-morbidities (often clustered as the metabolic syndrome), and can result in decreased life expectancy, with enormous costs to society. Even modest weight loss has been demonstrated to exhibit beneficial effects on the co-morbidities of obesity. While reduced caloric intake and increased physical activity, combined with behavioural modification, appears to be the most rational approach to weight reduction, it only offers short-lived success. For severely obese individuals, bariatric surgery has become an increasingly preferred option resulting in dramatic and well-maintained weight reductions followed by significant changes in obesity-related diseases.

Currently, few anti-obesity drugs are approved by regulatory authorities for long-term use (i.e. orlistat, sibutramine and rimonabant). Anti-obesity drug development is an active and dynamic field focusing on two major approaches: 1) inhibiting energy intake by addressing the input into the hypothalamic feeding centre or, 2) attempting to accelerate energy expenditure. Overcoming the hurdles of developing such medications is a daunting task, but it can be anticipated that several drugs in current development might become available within the next decade, and combination therapy of two or more agents could be the future of pharmacological prevention and treatment of obesity.

Key Words: anti-obesity drugs • bariatric surgery • diabetes • metabolic syndrome • obesity

The British Journal of Diabetes & Vascular Disease, Vol. 7, No. 3, 111-117 (2007)
DOI: 10.1177/14746514070070030301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Matfin Aspects of drug development and clinical trials -- Part 2 The British Journal of Diabetes & Vascular Disease, July 1, 2007; 7(4): 149 - 150. [PDF]